Dark

Check out our Dark Pool Levels

BCTXW
BriaCell Therapeutics Corp. Warrant
stock NASDAQ Warrant

At Close

Sep 17, 2025

0.0301USD-24.561%(-0.0098)10,100

0.00Bid 0.00Ask 0.0000Spread

Pre-market

0.00USD-100.000%(-0.04)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 19, 2022

04:58PM EST BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the Meeting) held virtually via teleconference on January 18, 2022 were passed. Voting for each of the director nominees was as follows: GlobeNewswire Inc

Dec 29, 2021

08:48PM EST BriaCell to Uplist and Trade on the Toronto Stock Exchange from GlobeNewswire Inc

Dec 16, 2021

08:00AM EST -- Insiders intend to acquire up to approximately 10% of BriaCells basic common shares, or 1.59 million shares -- Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased since program commencement -- $5.1 million proceeds received via warrant exercises since November 1, 2021 GlobeNewswire Inc

Dec 9, 2021

09:00AM EST BriaCell Summarizes Clinical Data Poster Presented at the 2021 San GlobeNewswire Inc

Nov 18, 2021

09:00AM EST BriaCell Adds Mary Crowley Cancer Research Center as a Clinical GlobeNewswire Inc

Nov 12, 2021

09:00AM EST BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates: GlobeNewswire Inc

Nov 5, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. GlobeNewswire Inc

Nov 2, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. GlobeNewswire Inc

Oct 5, 2021

09:00AM EDT October is Breast Cancer Awareness Month GlobeNewswire Inc

Sep 23, 2021

08:00AM EDT SmallCapVoice.com Inc. (SCV) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Companys continued growth. GlobeNewswire Inc

Sep 22, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the TSXV) has accepted the Companys Notice of Intention to implement a normal course issuer bid (the Buyback). GlobeNewswire Inc

Sep 9, 2021

09:00AM EDT BriaCell Announces Securities Buyback to Purchase up to 10% of GlobeNewswire Inc

Sep 1, 2021

09:15AM EDT BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors GlobeNewswire Inc

Aug 23, 2021

08:00AM EDT BriaCell to Participate at the H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Aug 19, 2021

08:00AM EDT BriaCell and ImaginAb Announce Collaboration to Evaluate GlobeNewswire Inc

Jul 14, 2021

07:24AM EDT BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced GlobeNewswire Inc

Jul 12, 2021

08:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the following virtual conferences: GlobeNewswire Inc

Jun 16, 2021

08:05AM EDT -- BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. -- Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021. GlobeNewswire Inc

Jun 10, 2021

08:05AM EDT BriaCell Therapeutics Announces Proceeds of US$12.88 Million from GlobeNewswire Inc

Jun 9, 2021

08:05AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that CEO Dr. William V. Williams will host a corporate and clinical update call on Wednesday, June 16, 2021 at 4:30 p.m. ET. GlobeNewswire Inc

Jun 7, 2021

07:50PM EDT BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million GlobeNewswire Inc

Jun 3, 2021

09:42AM EDT BriaCell Therapeutics Corp. Announces US$27.2 Million Private GlobeNewswire Inc

Jun 2, 2021

07:12AM EDT -- 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors(1) -- Top Responder: 21.4 months survival plus 100% resolution of eye-bulging orbital tumor -- Compares to 7.2-9.8 months survival in historical comparison treatment trials(2) GlobeNewswire Inc

May 19, 2021

05:15PM EDT BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting GlobeNewswire Inc

May 11, 2021

06:30AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences: GlobeNewswire Inc

Apr 21, 2021

08:00AM EDT SmallCapVoice.com Inc. (SCV) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (the Company), to discuss the Companys targeted immunotherapies for breast cancer and its unique position as a clinical-stage biotech company. GlobeNewswire Inc

Apr 15, 2021

06:00PM EDT BriaCell Announces Investor and Media Outreach Programs GlobeNewswire Inc

Apr 12, 2021

01:45PM EDT BriaCell Announces Closing of Over-Allotment Option in Connection GlobeNewswire Inc

06:30AM EDT Clinical and pathological data presented from the clinical trials of Bria-IMT alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival: GlobeNewswire Inc

Mar 30, 2021

06:30AM EDT BriaCell Therapeutics to Present at the American Association for GlobeNewswire Inc

Feb 26, 2021

02:25PM EST BriaCell Announces Closing of US$25 Million Public Offering GlobeNewswire Inc

Share